Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2009 June;34(2) > Minerva Endocrinoiogica 2009 June;34(2):137-47

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA ENDOCRINOLOGICA

A Journal on Endocrine System Diseases


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118


eTOC

 

REVIEWS  ADRENAL TUMORS


Minerva Endocrinoiogica 2009 June;34(2):137-47

language: English

Molecular basis of adrenocortical carcinomas

Soon P. S. H. 1,2, Sidhu S. B. 2,3

1 Department of Surgery, Bankstown Hospital and South West Clinical School University of New South Wales, Sydney, Australia
2 Kolling Institute of Medical Research University of Sydney, Sydney, Australia
3 Endocrine Surgical Unit University of Sydney, Sydney, Australia


PDF  


Adrenocortical carcinomas (ACCs) are rare tumors associated with poor prognosis. Although surgery is the mainstay of treatment for this cancer, most patients will experience a recurrence of their tumor. Adjuvant therapies currently include mitotane, radiotherapy and chemotherapy, but responses to these therapies, however, are poor. A better understanding of the molecular basis of this cancer is crucial to the development of newer and better treatment options. This review summarizes the current knowledge of the molecular basis of ACCs.

top of page

Publication History

Cite this article as

Corresponding author e-mail